Company intelligence / Profile preview
Zhifei Lvzhu
- Ownership
- Private
- Development stage
- Other
Overview
The company has five commercialized vaccines on the market in China and select international markets. These include several meningococcal conjugate/polysaccharide vaccines and a Hib conjugate vaccine. Over five additional candidates are in late-stage clinical or pre-commercial development. More than eleven new drug applications have been filed with Chinese regulators; at least five have completed Phase III studies. The company has supplied over 110 million doses worldwide since launch.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineRecombinant proteinConjugate vaccinePolysaccharide vaccineSynthetic biology-based vaccine
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Zhifei Lvzhu.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhifei Lvzhu.